Reiner Alexander P, Aragaki Aaron K, Gray Shelly L, Wactawski-Wende Jean, Cauley Jane A, Cochrane Barbara B, Kooperberg Charles L, Woods Nancy F, LaCroix Andrea Z
Women's Health Initiative Clinical Coordinating Center, Fred Hutchinson Cancer Research Center, Department of Epidemiology, School of Public Health and Community Medicine, University of Washington, Seattle, WA 98195, USA.
Am J Med. 2009 Oct;122(10):947-54. doi: 10.1016/j.amjmed.2009.04.016. Epub 2009 Aug 13.
The immune and blood coagulation systems have been implicated in the pathophysiology of the geriatric syndrome of frailty, but limited prospective data examining the relationship of clotting/inflammation biomarkers to risk of incident frailty exist.
This prospective analysis was derived from a nested case-control study within the Women's Health Initiative. Among women 65 to 79 years free of frailty at enrollment, we randomly selected 900 incident cases from those developing frailty within 3 years; 900 non-frail controls were individually matched on age, ethnicity, and blood collection date. Biomarkers assessed for risk of incident frailty included fibrinogen, factor VIII, D-dimer, C-reactive protein, interleukin-6, and tissue plasminogen activator (t-PA).
When examined by quartiles in multivariable adjusted models, higher D-dimer and t-PA levels were each associated with increased risk of frailty (P trend = .04). Relative to the lowest quartile, the odds ratios for frailty compared with the upper quartile were 1.52 (95% confidence interval, 1.05-2.22) for t-PA and 1.57 (95% confidence interval, 1.11-2.22) for D-dimer. For women having high t-PA and high D-dimer compared with women having lower levels of both biomarkers, the odds of frailty was 2.20 (1.29-3.75). There was little evidence for association between coagulation factor VIII, fibrinogen, C-reactive protein, or interleukin-6 levels and incident frailty.
This prospective analysis supports the role of markers of fibrin turnover and fibrinolysis as independent predictors of incident frailty in postmenopausal women.
免疫和血液凝固系统与衰弱这一老年综合征的病理生理学有关,但关于凝血/炎症生物标志物与新发衰弱风险之间关系的前瞻性数据有限。
这项前瞻性分析源自女性健康倡议中的一项巢式病例对照研究。在入组时无衰弱的65至79岁女性中,我们从3年内出现衰弱的女性中随机选取了900例新发病例;900名非衰弱对照根据年龄、种族和采血日期进行个体匹配。评估新发衰弱风险的生物标志物包括纤维蛋白原、凝血因子VIII、D-二聚体、C反应蛋白、白细胞介素-6和组织纤溶酶原激活物(t-PA)。
在多变量调整模型中按四分位数进行检查时,较高的D-二聚体和t-PA水平均与衰弱风险增加相关(P趋势=0.04)。相对于最低四分位数,t-PA与上四分位数相比衰弱的比值比为1.52(95%置信区间,1.05-2.22),D-二聚体为1.57(95%置信区间,1.11-2.22)。与两种生物标志物水平较低的女性相比,t-PA和D-二聚体水平都高的女性衰弱的几率为2.20(1.29-3.75)。几乎没有证据表明凝血因子VIII、纤维蛋白原、C反应蛋白或白细胞介素-6水平与新发衰弱之间存在关联。
这项前瞻性分析支持纤维蛋白周转和纤维蛋白溶解标志物作为绝经后女性新发衰弱独立预测指标的作用。